|
|||||
|
|
GlaxoSmithKline responds to the consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes |
|
| Authors: | P. Ambery and A. R. Cobitz |
| Affiliation: | (1) Cardiovascular, Metabolic and Musculoskeletal Centre of Excellence, GlaxoSmithKline, Uxbridge, Middlesex, UB11 1BT, UK;(2) Clinical Development, Medicines Development Centre—Metabolic, GlaxoSmithKline, Philadelphia, PA, USA |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |